Catalym develops antibodies against a placental factor which is overexpressed by various tumour types.
CatalYm has raised €100M across 2 funding rounds from 8 investors, most recently a Series C round in Nov 2022. Based in Munich, Germany; founded 2016; active in Healthtech. Data as of 6 Aug 2026.
Timing: overdue vs cohort gap · momentum flat. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2022-11-23 | Series C | €50M | Bayern Kapital,BioGeneration Ventures,Brandon Capital,Coparion,Forbion,Jeito Capital+2 more | View deal → |
| 2020-11-10 | Seed | €50M | — | View deal → |
